Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Clinical trial supply company strengthens its presence in the European Union
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Subscribe To Our Newsletter & Stay Updated
